CryoLife (CRY) Tops Q2 EPS by 2c, Slight Beat on Revenues

CryoLife (NYSE: CRY) reported Q2 EPS of $0.12, $0.02 better than the analyst estimate of $0.10. Revenue for the quarter came in at $47.8 million versus the consensus estimate of $47.01 million.

Second Quarter Highlights:

• Revenues Increased Two Percent Year-over-Year to $47.8 Million; Non-GAAP Revenues Increased Four Percent Year-over-Year
• Gross Margins were 69 Percent
• GAAP Net Income was $3.2 Million, or $0.09 Per Fully Diluted Common Share;
• Non-GAAP Net Income was $4.0 Million, or $0.12 Per Fully Diluted Common Share

For earnings history and earnings-related data on CryoLife (CRY) click here.

You May Also Be Interested In

• 908 Devices Inc. (MASS) Misses Q2 EPS by 17c ; Offers Guidance
• On Holding AG (ONON) Tops Q2 EPS by 2c; upgrades guidance
• Fennec Pharmaceuticals (FENC) Tops Q2 EPS by 3c